Robert H. Mealey

Robert H. Mealey

Auto-generated profile, based on publicly available information

Robert H. Mealey

Department of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, WA 99164-7040, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2013 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
LWL.N. Wise
L.N. Wise
LKLowell Kappmeyer
Lowell Kappmeyer
RMR.H. Mealey
R.H. Mealey
DKD.P. Knowles
D.P. Knowles
Equine piroplasmosis is caused by one of 2 erythrocytic parasites Babesia caballi or Theileria equi. Although the genus of the latter remains controversial, the most recent designation, Theileria, is utilized in this review. Shared pathogenesis includes tick‐borne transmission and erythrolysis leading to anemia as the primary clinical outcome. Although both parasites are able to persist indefinitely in their equid hosts, thus far, only B. caballi transmits across tick generations. Pathogenesis further diverges after transmission to equids in that B. caballi immediately infects erythrocytes, whereas T. equi infects peripheral blood mononuclear cells. The recent re‐emergence of T. equi in the United States has increased awareness of these tick‐borne pathogens, especially in terms of diagnosis and control. This review focuses in part on factors leading to the re‐emergence of infection and disease of these globally important pathogens.

9 November 2012 in BMC Genomics
Verified
Journal Article
Open access
PDF file
LKLowell Kappmeyer
Lowell Kappmeyer
MTMathangi Thiagarajan
Mathangi Thiagarajan
DHDavid R Herndon
David R Herndon
JRJoshua D Ramsay
Joshua D Ramsay
ECElisabet Caler
Elisabet Caler
KBKelly A. Brayton
Kelly A. Brayton
Background: Transmission of arthropod-borne apicomplexan parasites that cause disease and result in death or persistent infection represents a major challenge to global human and animal health. First described in 1901 as Piroplasma equi, this re-emergent apicomplexan parasite was renamed Babesia equi and subsequently Theileria equi, reflecting an uncertain taxonomy. Understanding mechanisms by which apicomplexan parasites evade immune or chemotherapeutic elimination is required for development of effective vaccines or chemotherapeutics. The continued risk of transmission of T. equi from clinically silent, persistently infected equids impedes the goal of returning the U. S. to non-endemic status. Therefore comparative genomic analysis of T. equi was undertaken to: 1) identify genes contributing to immune evasion and persistence in equid hosts, 2) identify genes involved in PBMC infection biology and 3) define the phylogenetic position of T. equi relative to sequenced apicomplexan parasites. Results: The known immunodominant proteins, EMA1, 2 and 3 were discovered to belong to a ten member gene family with a mean amino acid identity, in pairwise comparisons, of 39%. Importantly, the amino acid diversity of EMAs is distributed throughout the length of the proteins. Eight of the EMA genes were simultaneously transcribed. As the agents that cause bovine theileriosis infect and transform host cell PBMCs, we confirmed that T. equi infects equine PBMCs, however, there is no evidence of host cell transformation. Indeed, a number of genes identified as potential manipulators of the host cell phenotype are absent from the T. equi genome. Comparative genomic analysis of T. equi revealed the phylogenetic positioning relative to seven apicomplexan parasites using deduced amino acid sequences from 150 genes placed it as a sister taxon to Theileria spp. Conclusions: The EMA family does not fit the paradigm for classical antigenic variation, and we propose a novel model describing the role of the EMA family in persistence. T. equi has lost the putative genes for host cell transformation, or the genes were acquired by T. parva and T. annulata after divergence from T. equi. Our analysis identified 50 genes that will be useful for definitive phylogenetic classification of T. equi and closely related organisms.

10 January 2015 in Hepatology
Verified
Journal Article
Open access
PDF file
JRJoshua D. Ramsay
Joshua D. Ramsay
RERyan Evanoff
Ryan Evanoff
TWTom E. Wilkinson
Tom E. Wilkinson
TDThomas J. Divers
Thomas J. Divers
DKDonald P. Knowles
Donald P. Knowles
RMRobert H. Mealey
Robert H. Mealey
Equine hepacivirus (EHCV; nonprimate hepacivirus) is a hepatotropic member of theFlaviviridaefamily that infects horses. Although EHCV is the closest known relative to hepatitis C virus (HCV), its complete replication kineticsin vivohave not been described, and direct evidence that it causes hepatitis has been lacking. In this study, we detected EHCV in 2 horses that developed post‐transfusion hepatitis. Plasma and serum from these horses were used to experimentally transmit EHCV to 4 young adult Arabian horses, two 1‐month‐old foals (1 Arabian and 1 Arabian‐pony cross), and 2 foals (1 Arabian and 1 Arabian‐pony cross) with severe combined immunodeficiency (SCID). Our results demonstrated that EHCV had infection kinetics similar to HCV and that infection was associated with acute and chronic liver disease as measured by elevations of liver‐specific enzymes and/or by histopathology. Although most of these animals were coinfected with equine pegivirus (EPgV), also a flavivirus, EPgV viral loads were much lower and often undetectable in both liver and blood. Three additional young adult Arabian‐pony crosses and 1 SCID foal were then inoculated with plasma containing only EHCV, and evidence of mild hepatocellular damage was observed. The different levels of liver‐specific enzyme elevation, hepatic inflammation, and duration of viremia observed during EHCV infection suggested that the magnitude and course of liver disease was mediated by the virus inoculum and/or by host factors, including breed, age, and adaptive immune status.Conclusion: This work documents the complete infection kinetics and liver pathology associated with acute and chronic EHCV infection in horses and further justifies it as a large animal model for HCV. (Hepatology2015;61:1533–1546)

1 December 2014 in Veterinary Clinics of North America: Equine Practice
Verified
Journal Article
Closed access
LWL. Nicki Wise
L. Nicki Wise
APAngela M. Pelzel-McCluskey
Angela M. Pelzel-McCluskey
RMRobert H. Mealey
Robert H. Mealey
DKDonald P. Knowles
Donald P. Knowles

1 September 2017 in Experimental Parasitology
Verified
Journal Article
Closed access
WVWesley C. Van Voorhis
Wesley C. Van Voorhis
JDJ. Stone Doggett
J. Stone Doggett
MPMarilyn Parsons
Marilyn Parsons
MHMatthew A. Hulverson
Matthew A. Hulverson
RCRyan Choi
Ryan Choi
KOKayode K. Ojo
Kayode K. Ojo

6 September 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MUMassaro Ueti
Massaro Ueti
RMRobert H. Mealey
Robert H. Mealey
LKLowell Kappmeyer
Lowell Kappmeyer
Stephen WhiteStephen White
Stephen White
NKNancy Kumpula-McWhirter
Nancy Kumpula-McWhirter
DKDonald P. Knowles
Donald P. Knowles
Arthropod-borne apicomplexan pathogens that cause asymptomatic persistent infections present a significant challenge due to their life-long transmission potential. Although anti-microbials have been used to ameliorate acute disease in animals and humans, chemotherapeutic efficacy for apicomplexan pathogen elimination from a persistently infected host and removal of transmission risk is largely unconfirmed. The recent re-emergence of the apicomplexan Theileria equi in U.S. horses prompted testing whether imidocarb dipropionate was able to eliminate T. equi from naturally infected horses and remove transmission risk. Following imidocarb treatment, levels of T. equi declined from a mean of 104.9 organisms/ml of blood to undetectable by nested PCR in 24 of 25 naturally infected horses. Further, blood transfer from treated horses that became nested PCR negative failed to transmit to naïve splenectomized horses. Although these results were consistent with elimination of infection in 24 of 25 horses, T. equi-specific antibodies persisted in the majority of imidocarb treated horses. Imidocarb treatment was unsuccessful in one horse which remained infected as measured by nested PCR and retained the ability to infect a naïve recipient via intravenous blood transfer. However, a second round of treatment eliminated T. equi infection. These results support the utility of imidocarb chemotherapy for assistance in the control and eradication of this tick-borne pathogen. Successful imidocarb dipropionate treatment of persistently infected horses provides a tool to aid the global equine industry by removing transmission risk associated with infection and facilitating international movement of equids between endemic and non-endemic regions.